[Consensus on immunotherapy for small cell lung cancer(2024 edition)]
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Small cell lung cancer (SCLC) is aggressive, but new immunotherapies offer hope. Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors combined with chemotherapy are now standard first-line treatments for extensive-stage SCLC.
Area Of Science
- Oncology
- Immunotherapy
- Thoracic Oncology
Context
- Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor with high mortality.
- Approximately 70% of SCLC patients present with metastatic disease at diagnosis (extensive-stage SCLC).
- Traditional treatments like chemotherapy and radiotherapy offer limited long-term survival, with rapid recurrence.
Purpose
- To provide an expert consensus on the clinical application of immunotherapy for SCLC in China.
- To standardize the use of immune checkpoint inhibitors (ICIs) in SCLC treatment.
- To offer guidance to clinicians based on current evidence and guidelines.
Summary
- The advent of immune checkpoint inhibitors (ICIs), specifically PD-1/PD-L1 inhibitors, has significantly improved outcomes for extensive-stage SCLC (ES-SCLC).
- Combination therapy with PD-1/PD-L1 inhibitors and chemotherapy has become the new standard first-line treatment, prolonging overall survival.
- Several ICIs are now approved in China, expanding treatment options for SCLC patients.
Impact
- Improved survival rates and treatment options for patients with extensive-stage SCLC.
- Standardization of SCLC immunotherapy practices in China.
- Enhanced clinical decision-making for oncologists treating SCLC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...